44 related results for featured

Omega-3 in ASCENT, VITAL and REDUCE-IT Trials: What have We Learned?

Deepak L. Bhatt, MD, MPH
Brigham and Women’s Hospital
Boston, MA

Applying Cardiovascular Outcome Trial Data to T2DM Management

Darren K. McGuire, MD, MHSc
University of Texas Southwestern
Medical School
Dallas, TX

Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy: Past, Present and Future

Sanjiv J. Shah, MD
Northwestern University
Feinberg School of Medicine
Chicago, IL

Coronary Microvascular Dysfunction: A Causal Mechanistic Pathway for HFpEF?

Marcelo Fernando Di Carli, MD
Brigham and Women’s Hospital
Boston, MA

State of the Art Management of HFpEF and Glimpses Into the Future.

Sanjiv J. Shah, MD
Northwestern University
Feinberg School of Medicine
Chicago, IL

Immune Checkpoint-associated Myocarditis: A New Entity in Cardio-Oncology

Javid J. Moslehi, MD
Vanderbilt School of Medicine
Nashville, TN

Adipose-derived Cell-based Therapies for CVD: From Cells to Secretome

Keith March, MD, PhD, FACC
University of Florida College of Medicine
Gainesville, FL

ORBITA Redux / To Stent or Not: Yes, Revascularization is Still Standard of Care

Ajay J. Kirtane, MD, FACC
Columbia University Medical Center
New York, NY

Emerging Approaches to Dyslipidemia Management Beyond LDL-C

Eliot A. Brinton, MD, FAHA, FNLA
Utah Lipid Center
Salt Lake City, UT

Is it Time to Reappraise BP Targets to Further Reduce CVD Risk and Death?

William Cushman, MD, FACP
University of Tennessee College of Medicine
​Memphis, TN

Targeted Inhibition of Inflammation to Reduce Cardiovascular Event Rates: Lessons Learned From CANTOS

Paul M. Ridker, MD, FACC
Brigham and Women’s Hospital
​Boston, MA

LDL-C Lowering: Is Lowest Best?

Robert P. Giugliano, MD, FACC
Brigham and Women’s Hospital
​Boston, MA

Preventing Heart Failure and Providing CVD Protection in Patients with Diabetes

Darren K. McGuire, MD, MHSc, FACC
UT Southwestern Medical Center
​Dallas, TX

Gut Microbiota as a Target for Cardio-Renal Risk

W. H. Wilson Tang, MD, FACC
Cleveland Clinic
Cleveland, OH

What Have We Learned From Recent Trials for PAD and Where Are We Headed?

William R. Hiatt, MD
University of Colorado School of Medicine
Denver, CO 

HIV, Inflammation and Cardiovascular Disease

Priscilla Y. Hsue, MD, FACC
UCSF School of Medicine
San Francisco, CA

Utilizing Novel Therapies in Atherosclerosis: From Antibodies to Nanotechnology

Erik Stroes MD, PhD
Academic Medical Center
Amsterdam, Netherlands

Modifying CVD Risk by Managing Hyperglycemia: The Dawn of a New Era?

Jorge Plutzky, MD
Brigham and Women's Hospital
Boston, MA

Advancing the Cardiovascular Care of Our Cancer Patients: Where Are We Now?

Javid Moslehi, MD
Vanderbilt University
School of Medicine
Nashville, TN

Tailoring Oral Anticoagulation in Elderly Patients with Atrial Fibrilation

Christopher Granger, MD
Duke University
School of Medicine
Durham, NC

How We Should Manage HTN in Adults: The Importance of Diastolic Blood Pressure with Lower Systolic Targets

Deepak Bhatt, MD, MPH
Brigham and Women's Hospital 
Heart and Vascular Center
Boston, MA

Living with Heart Disease in Old Age: Shifting Priorites of Care for Older Cardiac Patients

Daniel Forman, MD
Professor, Department of Medicine
University of Pittsburgh

HFpEF in Older Adults: TTR Amyloid, Under Diagnosed and Treatable?

Mathew Maurer, MD
Columbia University
Medical Center
New York, NY

CKD: An Independent CV Risk Factor in the Elderly

George Bakris, MD
University of Chicago Medicine
Chicago, IL

No Automatic Prescribing in Those > 75 Years. Why Guideline Directed Clinician-Patient-Risk Discussion Crucial

Neil Stone, MD
Northwestern University
Feinburg School of Medicine
Chicago, IL

The Emerging Role of Gut Microbiota in CVD and Thrombosis.

Stanley L. Hazen, MD, PhD
Cleveland Clinic
Cleveland, OH

Reducing CV Risk with Glucose Lowering Drugs: Recent Breakthroughs.

Silvio E. Inzucchi, MD
Yale University School of Medicine
New Haven, CT

Eliminating Barriers That Prevent Optimal Stroke Prevention in Patients with Afib.

Christian T. Ruff, MD
Brigham and Women’s Hospital
Boston, MA

The Next Frontier in Heart Failure: Where Are We Going?

Scott D. Solomon, MD
Brigham and Women’s Hospital
Boston, MA 

Cardiorenal Disorders: Recent Advances, Novel Therapies.

Peter A. McCullough, MD, MPH
Baylor Heart and Vascular Institute
Dallas, TX

New Oral Interventions for Heart Failure.

Javed Butler,  MD, MPH
Stony Brooke University School of Medicine
Stony Brook, NY

PCSK9 and Atherosclerosis: Will We Target Risk with Monoclonal Antibodies or Only LDL-C?

Michael J. Koren, MD
Jacksonville Ctr. For Clinical Research

HDL Dysfunction in Coronary Artery Disease: An Enigma or Dead?

Stephen J. Nicholls, MBBS, PhD
South Australian Health and Medical Research Institute

Emerging Therapies on the Horizon for Hypertriglyceridemia

Ira Goldberg, MD
NYU Langone Medical Center

High LP(a): Causal Role in Calcific Stenosis and Other CV Diseases

Sotirios Tsimikas MD, UC San Diego School of Medicine

Direct Inhibition of Inflammation: CANTOS, CIRT, and Beyond

Paul M Ridker MD, Brigham and Women's Hospital

New Approaches to Modifying Risk by Improved Glycemic Management

Deepak L Bhatt MD, MPH, Harvard Medical School

Core Curriculum

Myocardial Ischemia Redefined: Optimal Care in CAD

View/Download individual slides (90 Slides)

Core Curriculum

Hyperglycemia and Acute Coronary Syndromes

View/Download individual slides (84 Slides)

Core Curriculum

New Frontiers in CVD Risk Management: Optimizing Outcomes in Patients with Multiple Cardiovascular Risks

View/Download individual slides (129 Slides)